Table 5

Significant associations of HLA-DP polymorphisms with frequencies of HBV mutations associates with liver disease riskd

HLA-DP SNPGenotype C HBV-infected subjectsGenotype B HBV-infected subjects
HBV mutationAdjusted OR (95% CI)HBV mutationAdjusted OR (95% CI)
rs3077
    CC1.001.00
    CTC1653T0.68 (0.48–0.95)
C1673T0.65 (0.43–0.99)
Pre-S1 start codon mutation1.56 (1.02–2.39)
    TTA1846T0.54 (0.30–0.97)G1719T2.97 (1.06–8.37)
G1896A0.47 (0.27–0.80)G1730C2.63 (1.01–6.85)
C10Aa0.40 (0.17–0.94)
Pre-S deletion0.43 (0.20–0.91)
rs3135021
    GG1.001.00
    GAC1673Tb0.54 (0.35–0.84)
Pre-S1 start codon mutation2.04 (1.34–3.11)
    AAA1727T2.95 (1.20–7.23)
A1846T0.47 (0.23–0.95)
rs9277535
    GG1.001.00
    GA
    AAT1674C/G0.62 (0.39–0.97)
A1846T0.62 (0.39–0.98)
rs2281388
    CC1.001.00
    CTT1674C/G1.47 (1.04–2.06)T1674C0.35 (0.14–0.87)
Pre-S deletion1.49 (1.02–2.17)G1719T0.41 (0.20–0.84)
Pre-S2 start codon mutation1.54 (1.02–2.33)G1652Ac0.46 (0.24–0.91)
A1C0.33 (0.13–0.82)
    TTA1846T1.61 (1.06–2.44)G1719T0.41 (0.18–0.93)
G1896A1.63 (1.11–2.42)
Pre-S2 start codon mutation1.99 (1.23–3.24)
Pre-S deletion1.90 (1.21–2.98)
  • a Represents highly correlated (phi coefficient, >0.7) mutations, including A31T, T49A, G105C, C109A, A135C, and G147C.

  • b Represents highly correlated (phi coefficient, >0.7) mutations, including A1652G, C1730G, and C1799G.

  • c Represents highly correlated (phi coefficient, > 0.7) mutations, including T1673C, G1730C, and G1799C.

  • d Boldface type indicates significant values.